Gilead Sciences, Inc. (GILD) Free Cash Flow CAGR:3.91%(TTM)
The free cash flow cagr for Gilead Sciences, Inc. (GILD) is +3.91% over the latest trailing 12-month period. Free cash flow CAGR uses precomputed cash-flow statement history.
The free cash flow cagr for Gilead Sciences, Inc. (GILD) stock is 3.91% over the past 12 months. The 3 year average growth rate is 6.84% and the 5 year cagr is 3.30%. Free cash flow CAGR measures how Gilead Sciences, Inc.'s cash generation has grown. FCF represents the cash available for dividends, buybacks, debt reduction, or reinvestment.
GILD Free Cash Flow CAGR Chart
Gilead Sciences, Inc. (GILD)
GILD Free Cash Flow CAGR History
| Year | Start FCF | End FCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $10.30B | $9.46B | $-849.00M | -8.24% | -8.24% |
| 2024 | $7.42B | $10.30B | +$2.88B | +38.86% | +38.86% |
| 2023 | $8.34B | $7.42B | $-923.00M | -11.06% | -11.06% |
| 2022 | $10.80B | $8.34B | $-2.46B | -22.78% | -22.78% |
| 2021 | $7.52B | $10.80B | +$3.29B | +43.72% | +43.72% |
| 2020 | $8.32B | $7.52B | $-801.00M | -9.63% | -9.63% |
| 2019 | $7.48B | $8.32B | +$843.00M | +11.28% | +11.28% |
| 2018 | $11.31B | $7.48B | $-3.83B | -33.89% | -33.89% |
| 2017 | $16.30B | $11.31B | $-4.99B | -30.62% | -30.62% |
| 2016 | $20.50B | $16.30B | $-4.20B | -20.50% | -20.50% |
| 2015 | $12.26B | $20.50B | +$8.24B | +67.22% | +67.22% |
| 2014 | $2.92B | $12.26B | +$9.35B | +320.62% | +320.62% |
| 2013 | $2.80B | $2.92B | +$117.00M | +4.18% | +4.18% |
| 2012 | $3.51B | $2.80B | $-709.11M | -20.22% | -20.22% |
| 2011 | $2.77B | $3.51B | +$735.08M | +26.52% | +26.52% |
| 2010 | $2.85B | $2.77B | $-77.97M | -2.74% | -2.74% |
| 2009 | $2.03B | $2.85B | +$821.62M | +40.51% | +40.51% |
| 2008 | $1.69B | $2.03B | +$341.63M | +20.25% | +20.25% |
| 2007 | $1.11B | $1.69B | +$573.90M | +51.57% | +51.57% |
| 2006 | $657.69M | $1.11B | +$455.16M | +69.21% | +69.21% |
| 2005 | $456.60M | $657.69M | +$201.09M | +44.04% | +44.04% |
| 2004 | $196.00M | $456.60M | +$260.60M | +132.96% | +132.96% |
| 2003 | $56.81M | $196.00M | +$139.19M | +244.99% | +244.99% |
| 2002 | $-153.31M | $56.81M | +$210.12M | +0.00% | N/A |
| 2001 | $-53.82M | $-153.31M | $-99.49M | +0.00% | N/A |
| 2000 | $-75.10M | $-53.82M | +$21.28M | +0.00% | N/A |
| 1999 | $-62.30M | $-75.10M | $-12.80M | +0.00% | N/A |
| 1998 | $-68.30M | $-62.30M | +$6.00M | +0.00% | N/A |
| 1997 | $-20.20M | $-68.30M | $-48.10M | +0.00% | N/A |
Quarterly Free Cash Flow — QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $2.43B | -22.2% | +46.8% |
| Q4 2025 | $3.12B | -21.2% | +10.4% |
| Q3 2025 | $3.96B | +450.1% | -5.0% |
| Q2 2025 | $720.00M | -56.4% | -39.7% |
| Q1 2025 | $1.65B | -41.5% | -21.8% |
| Q4 2024 | $2.83B | -32.1% | +44.7% |
| Q3 2024 | $4.17B | +248.8% | +155.2% |
| Q2 2024 | $1.20B | -43.5% | -45.7% |
| Q1 2024 | $2.11B | +8.2% | +29.3% |
| Q4 2023 | $1.95B | +19.7% | -18.1% |
| Q3 2023 | $1.63B | -25.7% | -39.7% |
| Q2 2023 | $2.20B | +34.5% | +32.5% |
| Q1 2023 | $1.64B | -31.5% | +2.6% |
| Q4 2022 | $2.39B | -11.8% | -21.7% |
| Q3 2022 | $2.71B | +63.1% | -13.1% |
| Q2 2022 | $1.66B | +4.1% | -24.5% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Daniel O'Day